Scarica l'app Stockscreener
22.09
0.32%
-0.07
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Blue Owl Capital Holdings LP Invests $28.04 Million in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results - geneonline.com
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Is Cullinan Therapeutics (CGEM) Fully Valued After Its Phase 3 Trial Win? - simplywall.st
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com Australia
Cullinan Therapeutics (CGEM) to Present Phase 3 REZILIENT3 Trial - GuruFocus
Taiho, Cullinan trial results selected for lung cancer conference - Investing.com
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer - marketscreener.com
Cullinan's lung cancer trial met its main goal; results are set for presentation in September - Stock Titan
Cullinan Oncology stock hits 52-week high at 21.55 USD By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Morgan Stanley Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 1-Year HighShould You Buy? - MarketBeat
UBS Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $27 - Moomoo
UBS raises Cullinan Oncology stock price target to $27 on trial data - Investing.com
HC Wainwright Reaffirms Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
CGEM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $30 - GuruFocus
Cullinan Therapeutics (CGEM) Advances in Phase 3 Trial, Shares Near 2-Year High Amid Mixed Signals - GuruFocus
Assenagon Asset Management S.A. Sells 77,023 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 30,000 Shares - MarketBeat
Cullinan Therapeutics (CGEM) investor group discloses 6,491,123-share position - Stock Titan
Cullinan Therapeutics (CGEM): T. Rowe Price reports 6.2% ownership stake - Stock Titan
CGEM (CGEM) insider to sell 30,000 shares after stock option exercise - Stock Titan
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Op - Benzinga
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - MarketBeat
CGEM Maintains Outperform Rating -- Price Target Raised to $42.0 - GuruFocus
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $42.00 - MarketBeat
Cullinan Therapeutics (CGEM) Shares Rise 6% Premarket on Positiv - GuruFocus
New Taiho, Cullinan data heats up lung cancer drug battle - Yahoo Finance
Show Me The Money: Did You Miss CGEM's Rally? Here's What Comes Next - RTTNews
Cullinan rises on trial win for lung cancer drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan: REZILIENT3 Phase 3 Interim Shows Improved PFS for Zipalertinib + Chemo - TradingView
Cullinan Therapeutics, Inc. $CGEM Shares Bought by The Manufacturers Life Insurance Company - MarketBeat
Cullinan Therapeutics Says Phase 3 Trial of Experimental Lung Cancer Drug Met Primary Endpoint - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - BioSpace
Zipalertinib trial meets primary endpoint in lung cancer study - Investing.com Nigeria
Zipalertinib trial meets primary endpoint in lung cancer study By Investing.com - Investing.com Australia
HC Wainwright Issues Pessimistic Outlook for CGEM Earnings - MarketBeat
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews
Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com - Investing.com UK
Cullinan says zipalertinib plus chemotherapy meets PFS endpoint in Phase 3 REZILIENT3 lung cancer trial - Bitget
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 52-Week HighStill a Buy? - MarketBeat
Possible Bearish Signals With Cullinan Therapeutics Insiders Disposing Stock - Moomoo
Cullinan Oncology stock hits 52-week high at 19.43 USD - Investing.com
Cullinan Therapeutics (CGEM) Wins FDA Backing For CLN 049, Is The Upside Already Priced In? - Sahm
Dimensional Fund Advisors LP Has $12.87 Million Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results - MarketBeat
Cullinan Therapeutics Inc (CGEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cullinan Therapeutics (CGEM): State Street discloses 3.67M-share, 6% ownership stake - Stock Titan
The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following FDA-Backed Phase 2 CLN-049 Trial - Yahoo Finance
Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Cullinan Therapeutics, Inc. Stock 12‑Month Price Target Raised to $33, Implies 87% Upside - TradingView
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):